The original disclosure in Japanese was released on Jan. 30, 2017 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2016
FY2017 (April 1, 2016 - March 31, 2017) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): February 10, 2017

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2016 (April 1, 2016 – December 31, 2016)

(1) Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2016		Nine months ended December 31, 2015	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	172,218	1.2	170,250	2.5
Operating income(loss)	12,741	26.3	10,091	(4.6)
Ordinary income(loss)	13,403	23.4	10,858	(1.0)
Net income (loss) attributable to owners of the parent	8,876	35.6	6,546	9.4
Net income (loss) per share (Yen)	44.11		32.53	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	1,558	(66.7)	4,679	(47.6)

(2) Financial position

	As of December 31, 2016	As of March 31, 2016
	(Millions of yen)	(Millions of yen)
Total assets	269,737	253,253
Net assets	158,981	156,148
Equity ratio (%)	48.3	51.5
(Reference) Equity	130,334	130,386

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2016	Year ending March 31, 2017	Year ending March 31, 2017 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	12.00		13.00
Annual	12.00		13.00

Notes: Correction of dividend forecast from the most recent dividend forecast : Yes
The year-end dividend for FY2016 included a commemorative dividend of ¥1.00

3. Forecast for the year ending March 31, 2017 (April 1, 2016 – March 31, 2017)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2017	
	(Millions of yen)	(%)
Net sales	234,100	3.9
Operating income(loss)	13,100	12.1
Ordinary income(loss)	13,800	7.5
Net income (loss) attributable to owners of the parent	8,300	17.6
Net income (loss) per share (Yen)	41.25	

Note: Correction of financial forecast from the most recent financial forecast : Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in specific subsidiaries) : No

(2) Applying of specific accounting treatments of the quarterly consolidated financial statements : No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of December 31, 2016 : 217,699,743
As of March 31, 2016 : 217,699,743
2) Number of treasury stocks at year end
As of December 31, 2016 : 16,475,585
As of March 31, 2016 : 16,475,391
3) Average number of outstanding shares
Nine months ended December 31, 2016 : 201,224,286
Nine months ended December 31, 2015 : 201,225,138

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2016 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2 Summary Information (Notes) ---------- 4
   (1) Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
   (2) Additional Information---------- 4
3. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 7
   Consolidated Quarterly Statements of Income
   (For the Nine Months Ended December 31, 2016 and 2015) ---------- 7
   Consolidated Quarterly Statements of Comprehensive Income
   (For the Nine Months Ended December 31, 2016 and 2015) ---------- 8
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 9
   (Notes on Premise of Going Concern) ---------- 9
   (Notes on Material Changes in Shareholders' Equity) ---------- 9
   (Segment Information) ---------- 9
   (Significant Subsequent Events) ---------- 10
○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2016

(1) Consolidated Financial Results

In the nine months ended December 31, 2016, although the Japanese economy maintained a moderate recovery as the hiring and income environment improved, personal spending remained weak.

On the other hand, overseas, while the American economy continued on a recovery path, there was continued uncertainty for the future of the global economy caused by the downside risk in emerging country economies, the Brexit issue in the U.K., the impact of future policies in the U.S. and other issues.

Under these economic circumstances, moving into the final fiscal year of the Takara Group Medium-Term Management Plan FY2017, which is the second step of efforts toward achieving the Takara Group Vision 2020, our long-term vision, the Group continued to make efforts to improve domestic business profitability and to expand and grow our overseas business while working on steady business activities with aim of transforming into a well-balanced business structure that can hold up well to business environment changes by accelerating growth in our Biomedical Business.

As a result, in the nine months ended December 31, 2016, net sales were up by 1.2% year on year to ¥172,218 million. Gross profit rose 4.4% year on year to ¥70,881 million. Operating income increased by 26.3% year on year to ¥12,741 million while ordinary income rose 23.4% year on year to ¥13,403 million. Net income attributable to owners of the parent increased by 35.6% year on year to ¥8,876 million.

Results by business segment were as follows.

[Takara Shuzo Group]

For alcoholic beverages, in the nine months ended December 31, 2016, while sales of shochu declined year on year, sake sales were flat compared with the same period of the previous fiscal year. Sales of light-alcohol refreshers increased as sales of Takara Shochu High Ball remained robust.

As sales of other alcoholic beverages such as whiskey also rose, sales of alcoholic beverages overall increased.

In the Seasonings Business, sales increased due to healthy sales of mirin and cooking sake. Sales of raw alcohol, etc. also increased, whereas transportation sales declined.

In the Japanese Food Wholesale Business in overseas markets, sales grew as businesses at FOODEX S.A.S. (France), Cominport Distribución S.L. (Spain), and others remained buoyant.

As a result, net sales for the Takara Shuzo Group rose 1.3% year on year to ¥148,818 million. Cost of sales increased by 0.2% to ¥92,152 million. Consequently, gross profit rose 3.3% year on year to ¥56,666 million. SG&A expenses were up by 1.0% year on year to ¥47,252 million due to the increases in promotion expenses and transportation expenses.

Accordingly, the Takara Shuzo Group recorded operating income up 16.4% year on year to ¥9,413 million in the nine months ended December 31, 2016.

[Takara Bio Group]

Net sales for the nine months ended December 31, 2016 decreased by 0.3% year on year to ¥20,645 million despite increased sales on a local currency basis overseas, reflecting the stronger Japanese yen. Cost of sales decreased by 11.9% year on year to ¥8,106 million as the cost rate fell due to changes in the structure of sales for each product and other factors. Consequently, gross profit increased by 9.0% year on year to ¥12,538 million. SG&A expenses decreased by 2.5% year on year to ¥9,813 million due to the declines in research and development expenses and other expenses. As a result, the Takara Bio Group recorded operating income up 88.6% year on year to ¥2,724 million in the nine months ended December 31, 2016.

[Takara Healthcare]

Net sales for the nine months ended December 31, 2016 fell by 2.8% year on year to ¥1,337 million due to falling sales of OEM cosmetics. Cost of sales was down by 21.5% year on year to ¥510 million. Consequently, gross profit increased by 13.9% year on year to ¥826 million. SG&A expenses were up by 18.7% year on year to ¥813 million, mainly due to the increases in promotion expenses and administrative expenses. As a result, Takara Healthcare's operating income decreased by 67.8% year on year to ¥13 million.

[Other]

Net sales of business segments other than the reported segments for the nine months ended December 31, 2016 increased by 2.2% year on year to ¥4,465 million. Cost of sales increased by 0.5% year on year to ¥3,857 million. Consequently, gross profit increased by 14.4% year on year to ¥608 million. SG&A expenses were up by 0.3% year on year to ¥501 million. As a result, operating income grew by 231.1% year on year to ¥107 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2015, to December 31, 2015)	Period under Review (from April 1, 2016, to December 31, 2016)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	45,539	44,569	97.9
Sake	19,848	19,855	100.0
Light-alcohol refreshers	21,263	23,698	111.5
Other alcoholic beverages	10,458	10,592	101.3
Alcoholic beverages total	97,110	98,716	101.7
Hon Mirin	11,933	11,987	100.4
Other seasonings	7,199	7,603	105.6
Seasonings total	19,133	19,590	102.4
Raw alcohol, etc.	5,432	5,667	104.3
Transportation	8,922	8,039	90.1
Japanese food wholesales business in overseas markets	15,164	15,759	103.9
Other	1,096	1,044	95.3
Total	146,859	148,818	101.3
Takara Bio Group	20,706	20,645	99.7
Takara Healthcare	1,376	1,337	97.2
Other	4,369	4,465	102.2
Sales not allocated to business segments and intersegment transactions	(3,061)	(3,048)	-
Total	**170,250**	**172,218**	**101.2**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥269,737 million as of December 31, 2016, up by ¥16,484 million from March 31, 2016. Current assets stood at ¥172,857 million, up by ¥13,784 million. This increase primarily resulted from increases of ¥6,456 million in cash and deposits, ¥15,234 million in notes and accounts receivable-trade and ¥2,976 million in merchandise and finished goods, despite a decline of ¥11,528 million in securities.

Noncurrent assets increased by ¥2,700 million from the end of the previous fiscal year to ¥96,880 million. The main factors were increases of ¥3,854 million in property, plant and equipment and ¥833 million in investments and other assets, including investment securities, and a decrease of ¥1,988 million in intangible assets.

Total liabilities amounted to ¥110,756 million as of December 31, 2016, up by ¥13,652 million from March 31, 2016. Current liabilities rose ¥20,421 million from the end of the previous fiscal year to ¥68,069 million. This was primarily due to increases of ¥1,455 million in notes and accounts payable–trade, ¥3,010 million in short-term loans payable, ¥10,000 million in current portion of bonds and ¥4,729 million in accrued alcohol tax.

Noncurrent liabilities declined ¥6,769 million from the end of the previous fiscal year to ¥42,686 million. This was primarily due to a ¥10,000 million decrease resulting from the transfer of bonds to current liabilities, whereas long-term loans payable and other non-current liabilities including deferred tax liabilities increased by ¥1,061 million and by ¥2,073 million, respectively.

Net assets stood at ¥158,981 million as of December 31, 2016, up ¥2,832 million from the end of the previous fiscal year. The main factors were increases of ¥6,461 million in retained earnings, ¥2,777 million in valuation difference on available-for-sale securities and ¥2,884 million in non-controlling interests, and a decline of ¥9,720 million in foreign currency translation adjustment.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the consolidated forecasts for the fiscal year ending March 31, 2017 released on November 10, 2016, based on consideration of business performance in the nine months ended December 31, 2016 and recent performance trends.

Consolidated net sales are unchanged from the previous forecast, as net sales for both Takara Shuzo Group and Takara Bio Group are in line with the forecast.

Meanwhile, due to the steady performance of the domestic alcoholic beverages business and the upswing in business results at overseas subsidiaries at Takara Shuzo Group, as well as Takara Bio Group's projected performance surpassing the forecast by revenues from gene therapy and other factors, income is expected to exceed the plan. Accordingly, the Company revised its forecast upwards for consolidated operating income by ¥500 million, consolidated ordinary income by ¥500 million, and net income attributable to owners of the parent by ¥100 million, respectively.

2. Summary Information (Notes)

(1) Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

In the three month period ended June 30, 2016, certain consolidated subsidiaries applied Practical Solution on a change in depreciation method due to Tax Reform 2016 (PITF No. 32, June 17, 2016) following the revision of the Corporation Tax Act, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on operating income, ordinary income, and profit before income taxes and minority interests for the nine month period ended December 31, 2016 is immaterial.

(2) Additional Information

(Application of Revised Implementation Guidance on Recoverability of Deferred Tax Assets)

The Company has been applying the Revised Implementation Guidance on Recoverability of Deferred Tax Assets (ASBJ Guidance No. 26 of March 28, 2016) from the beginning of the three month period ended June 30, 2016.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2016	As of Dec. 31, 2016
Assets		
Current assets		
Cash and deposits	38,386	44,843
Notes and accounts receivable-trade	53,602	68,837
Securities	28,238	16,710
Merchandise and finished goods	29,739	32,715
Work in process	1,077	1,091
Raw materials and supplies	3,401	3,645
Other	4,859	5,246
Allowance for doubtful accounts	(231)	(232)
Total current assets	159,073	172,857
Noncurrent assets		
Property, plant and equipment	53,065	56,919
Intangible assets		
Goodwill	6,975	5,835
Other	4,035	3,187
Total intangible assets	11,010	9,022
Investments and other assets		
Investment securities	24,747	25,527
Other	5,468	5,502
Allowance for doubtful accounts	(112)	(92)
Total investments and other assets	30,103	30,937
Total noncurrent assets	94,179	96,880
Total assets	253,253	269,737

(Millions of Yen)

	As of Mar. 31, 2016	As of Dec. 31, 2016
Liabilities		
Current liabilities		
Notes and accounts payable-trade	15,201	16,656
Short-term loans payable	4,994	8,004
Current portion of bonds	-	10,000
Accrued alcohol tax	7,855	12,584
Accrued expenses	4,965	5,728
Income taxes payable	2,307	2,501
Provision for sales promotion expenses	1,870	2,264
Other provision	2,319	1,696
Other	8,133	8,633
Total current liabilities	47,648	68,069
Noncurrent liabilities		
Bonds payable	20,000	10,000
Long-term loans payable	10,255	11,316
Net defined benefit liability	8,544	8,660
Long-term deposits received	5,379	5,358
Other	5,277	7,350
Total noncurrent liabilities	49,456	42,686
Total liabilities	97,104	110,756
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,879	1,650
Retained earnings	113,663	120,125
Treasury stock	(9,938)	(9,938)
Total shareholders' equity	118,830	125,063
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	6,822	9,600
Deferred gains or losses on hedges	(445)	223
Foreign currency translation adjustment	5,548	(4,172)
Remeasurements of defined benefit plans	(370)	(380)
Total accumulated other comprehensive income	11,555	5,271
Noncontrolling interests	25,762	28,646
Total net assets	156,148	158,981
Total liabilities and net assets	253,253	269,737

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Nine Months Ended December 31, 2016 and 2015)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – Dec. 31, 2015)	FY2017 (Apr. 1, 2016 – Dec. 31, 2016)
Net sales	170,250	172,218
Cost of sales	102,349	101,336
Gross profit	67,901	70,881
Selling, general and administrative expenses	57,809	58,139
Operating income	10,091	12,741
Non-operating income		
Dividends income	436	453
Equity in earnings of affiliates	275	242
Other	533	432
Total non-operating income	1,245	1,128
Non-operating expenses		
Interest expenses	335	321
Other	143	144
Total non-operating expenses	479	466
Ordinary income	10,858	13,403
Extraordinary income		
Gain on sales of noncurrent assets	—	864
Other	327	66
Total extraordinary income	327	931
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	—	199
Loss on valuation of investment securities	148	108
Other	51	17
Total extraordinary losses	199	325
Income before income taxes and minority interests	10,986	14,009
Income taxes-current	4,168	4,461
Income taxes-deferred	(122)	(13)
Total income taxes	4,046	4,448
Net income	6,940	9,560
Net income attributable to the noncontrolling interest	393	684
Net income attributable to owners of the parent	6,546	8,876

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Nine Months Ended DEcember 31, 2016 and 2015)

(Millions of Yen)

	FY2016 (Apr. 1, 2015 – Dec. 31, 2015)	FY2017 (Apr. 1, 2016 – Dec. 31, 2016)
Net income	6,940	9,560
Other comprehensive income		
Valuation difference on available-for-sale securities	(56)	2,777
Deferred gains or losses on hedges	(425)	668
Foreign currency translation adjustment	(1,732)	(11,449)
Remeasurements of defined benefit plans	(34)	0
Share of other comprehensive income of associates accounted for using equity method	(11)	—
Total other comprehensive income	(2,260)	(8,002)
Comprehensive income	4,679	1,558
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	4,568	2,592
Comprehensive income attributable to noncontrolling interest	110	(1,033)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2015, to December 31, 2015)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	146,673	20,048	1,374	168,097	1,807	169,904	346	170,250
Intersegment	185	657	1	845	2,561	3,407	(3,407)	-
Total	146,859	20,706	1,376	168,942	4,369	173,311	(3,061)	170,250
Segment income (loss)	8,085	1,444	40	9,570	32	9,603	488	10,091

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥28 million and income of the Company not allocated to business segments of ¥459 million.
3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2016, to December 31, 2016)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	148,648	20,036	1,335	170,021	1,851	171,872	345	172,218
Intersegment	169	608	1	779	2,614	3,394	(3,394)	-
Total	148,818	20,645	1,337	170,801	4,465	175,267	(3,048)	172,218
Segment income	9,413	2,724	13	12,151	107	12,259	482	12,741

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥65 million and income of the Company not allocated to business segments of ¥416 million.
3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

As stated in Change in Accounting Policy, in the three month period ended June 30, 2016, certain consolidated subsidiaries applied Practical Solution on a change in depreciation method due to Tax Reform 2016, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on segment income for the nine month period ended December 31, 2016 is immaterial.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

An impairment loss of ¥199 million has been recorded in the Takara Bio Group segment.

(Significant Subsequent Events)

(Merger through share acquisition)

Takara Bio USA Holdings Inc.(“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc., executed a merger agreement with Rubicon Genomics, Inc.(“Rubicon”) pursuant to which Takara Bio USA acquired Rubicon’s shares, making it a subsidiary, on December 15, 2016, and completed the acquisition on January 17, 2017.

(1) Purpose of the share acquisition

Takara Bio Group has been focused on the development of next generation sequencing (NGS) reagent kits, which are used in a variety of fields ranging from basic research through industrial applications. By welcoming Rubicon into Takara Bio Group, Rubicon’s sample preparation technologies for ultra-low input DNA sequencing analysis complement Takara Bio Group’s sample preparation technologies for ultra-low input RNA sequencing analysis, allowing the Group to provide a broader range of products and services in the area of ultra-low input nucleic acid analysis.

Furthermore, with the addition of preparation systems (instruments) for NGS of WaferGen Bio Systems, Inc., which is planned to be acquired by the Group in March 2017, Takara Bio Group will expand its products and services lineup across a wide range of area from basic research through industrial applications.

(2) Name of the counterparty to the share acquisition

Management and other shareholders of the company to be acquired

(3) Name, business contents and scale of the counterparty to be acquired

1) Name: Rubicon Genomics, Inc.
2) Location: 4743 Venture Drive, Ann Arbor, MI 48108 United States
3) Representative: Dr. James Koziarz, CEO
4) Business: Manufacturing and sales of research reagents
5) Operating performance and financial position of the company for the fiscal year ended December 31, 2015:
Capital: 13,249 Thousand U.S. Dollars
Net assets: (447) Thousand U.S. Dollars
Total assets: 4,338 Thousand U.S. Dollars
Net sales: 8,346 Thousand U.S. Dollars
Operating income: 1,460 Thousand U.S. Dollars

(4) Time of the share acquisition

January 17, 2017

(5) Number of shares to be acquired, acquisition price and percentage of ownership after acquisition of shares

1) Number of shares owned before acquisition: 0 shares
2) Number of shares to be acquired: common stock: 23,006,790 shares (Number of voting rights: 23,006,790)
3) Acquisition price of Rubicon’s common stock: 75,000 Thousand U.S. Dollars
4) Number of shares owned after acquisition of common stock: 23,006,790 shares
(Number of voting rights: 23,006,790, ownership ratio of voting rights: 100%)

(6) Fund procurement and payment methods

The acquisition will be fully funded with Takara Bio Group’s own funds.

平成29年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2016

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
   Takara Shuzo Group
   要約損益計算書
   Statements of Income (Summary)

3. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

4. 平成29年3月期第3四半期　参考資料
   Reference Data for the Third Quarter Ended December 31, 2016

5. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

6. 平成29年3月期　連結業績予想数値の修正
   Revision of Consolidated Business Results Forecast for the Year Ending March 31, 2017

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部
Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)

(百万円 Millions of Yen)

	平成28年3月期 第3四半期累計	平成29年3月期 第3四半期累計 Apr. 1, 2016 - Dec. 31, 2016		
	実績(a) FY2016(1Q-3Q) Actual (a)	実績(b) FY2017(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 グループ Takara Shuzo Group	146,859	148,818	1,959	101.3%
タカラバイオ グループ Takara Bio Group	20,706	20,645	△ 61	99.7%
宝ヘルスケア Takara Healthcare Inc.	1,376	1,337	△ 39	97.2%
その他 Other, net	1,308	1,417	108	108.3%
売上高 Net sales	170,250	172,218	1,967	101.2%
売上原価 Cost of sales	102,349	101,336	△ 1,012	99.0%
売上総利益 Gross profit	67,901	70,881	2,980	104.4%
運送費、保管料 Transportation and storage	6,574	6,737	162	102.5%
広告宣伝費 Advertising	2,790	2,675	△ 114	95.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	24,561	25,020	459	101.9%
研究開発費 Research and development	3,363	3,155	△ 208	93.8%
管理費、その他 Other, net	20,519	20,550	30	100.1%
販売費及び一般管理費 SG&A expenses	57,809	58,139	330	100.6%
宝酒造 グループ Takara Shuzo Group	8,085	9,413	1,328	116.4%
タカラバイオ グループ Takara Bio Group	1,444	2,724	1,280	188.6%
宝ヘルスケア Takara Healthcare Inc.	40	13	△ 27	32.2%
その他 Other, net	520	589	69	113.3%
営業利益(△:損失) Operating income(Δ:loss)	10,091	12,741	2,649	126.3%
受取利息・配当金 Interest and Dividends income	630	581	△ 48	92.2%
その他営業外収益 Other, net	614	546	△ 68	88.9%
営業外収益 Non-operating income	1,245	1,128	△ 116	90.6%
支払利息 Interest and discounts expenses	335	321	△ 13	95.9%
その他営業外費用 Other, net	143	144	1	100.7%
営業外費用 Non-operating expenses	479	466	△ 12	97.3%
経常利益(△:損失) Ordinary income(Δ:loss)	10,858	13,403	2,545	123.4%
特別利益 Extraordinary income	327	931	603	284.4%
特別損失 Extraordinary loss	199	325	126	163.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	10,986	14,009	3,022	127.5%
法人税、住民税及び事業税 Current income taxes	4,168	4,461	293	107.0%
法人税等調整額 Deferred income taxes	△ 122	△ 13	109	―
四半期純利益(△:損失) Net income(Δ:loss)	6,940	9,560	2,620	137.8%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	393	684	290	173.9%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	6,546	8,876	2,329	135.6%
設備投資額(有形・無形) Capital expenditures	3,768	3,749	△ 19	99.5%
減価償却費(有形・無形) Depreciation and Amortization	3,820	3,753	△ 67	98.2%
のれん償却額 Amortization of goodwill	404	349	△ 55	86.4%

営業外収益 Non-operating income	受取利息127、受取配当金453、持分法による投資利益242、補助金収入100 など Interest income 127, Dividends income 453, Equity in earnings of affiliates 242, Subsidy income 100, etc.
営業外費用 Non-operating expenses	支払利息128、社債利息193 など Interest expense 128, Interest on bonds 193, etc.
特別利益 Extraordinary income	段階取得に係る差益864 など Gain on step acquisitions 864, etc.
特別損失 Extraordinary loss	減損損失199、固定資産除売却損108 など Impairment loss 199, Loss on sales and retirement of noncurrent assets 108, etc.

2. 宝酒造グループ Takara Shuzo Group

要約損益計算書 Statements of Income (Summary)

（百万円 Millions of Yen）

	平成28年3月期 第3四半期累計	平成29年3月期 第3四半期累計 Apr. 1, 2016 - Dec. 31, 2016		
	実績(a) FY2016(1Q-3Q) Actual (a)	実績(b) FY2017(1Q-3Q) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	45,539	44,569	△ 970	97.9%
清酒 Sake	19,848	19,855	7	100.0%
ソフトアルコール飲料 Light-alcohol refreshers	21,263	23,698	2,435	111.5%
その他酒類 Other liquors	10,458	10,592	134	101.3%
本みりん Hon Mirin	11,933	11,987	53	100.4%
その他調味料 Other seasonings	7,199	7,603	403	105.6%
原料用アルコール等 Raw alcohol	5,432	5,667	234	104.3%
海外日本食材卸 Japanese food wholesale business in overseas markets	15,164	15,759	595	103.9%
その他 Other	10,018	9,083	△ 934	90.7%
売上高 Net sales	146,859	148,818	1,959	101.3%
売上原価 Cost of sales	91,986	92,152	166	100.2%
売上総利益 Gross profit	54,872	56,666	1,793	103.3%
運送費、保管料 Transportation and storage	6,002	6,190	188	103.1%
広告宣伝費 Advertising	2,382	2,278	△ 104	95.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,759	24,287	527	102.2%
研究開発費 Research and development	242	254	12	105.2%
管理費、その他 Other, net	14,400	14,241	△ 158	98.9%
販売費及び一般管理費 SG&A expenses	46,787	47,252	465	101.0%
営業利益（△：損失） Operating income(Δ:loss)	8,085	9,413	1,328	116.4%
営業外収益 Non-operating income	580	496	△ 83	85.6%
営業外費用 Non-operating expenses	308	240	△ 67	78.0%
経常利益（△：損失） Ordinary income(Δ:loss)	8,357	9,669	1,312	115.7%
特別利益 Extraordinary income	62	903	840	1434.7%
特別損失 Extraordinary loss	168	60	△ 107	36.2%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	8,251	10,512	2,260	127.4%
法人税、住民税及び事業税 Current income taxes	2,616	3,093	476	118.2%
法人税等調整額 Deferred income taxes	62	81	18	129.5%
四半期純利益（△：損失） Net income(Δ:loss)	5,572	7,337	1,765	131.7%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	149	65	△ 84	43.8%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	5,422	7,271	1,849	134.1%
設備投資額（有形・無形） Capital expenditures	1,783	1,675	△ 107	94.0%
減価償却費（有形・無形） Depreciation and Amortization	2,396	2,298	△ 97	95.9%
のれん償却額 Amortization of goodwill	268	227	△ 41	84.6%

3. タカラバイオグループ Takara Bio Group

要約損益計算書 Statements of Income (Summary)

（百万円 Millions of Yen）

	平成28年3月期 第3四半期累計	平成29年3月期 第3四半期累計 Apr. 1, 2016 - Dec. 31, 2016		
	実績(a) FY2016(1Q-3Q) Actual (a)	実績(b) FY2017(1Q-3Q) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	14,487	14,099	△ 388	97.3%
理化学機器 Scientific instruments	2,276	1,909	△ 366	83.9%
受託・その他 Contracted service and other	2,114	2,410	296	114.0%
バイオ産業支援　計 Bioindustry	18,878	18,420	△ 458	97.6%
遺伝子医療 Gene Therapy	−	500	500	−
医食品バイオ AgriBio	1,828	1,724	△ 103	94.3%
売上高 Net sales	20,706	20,645	△ 61	99.7%
売上原価 Cost of sales	9,199	8,106	△ 1,093	88.1%
売上総利益 Gross profit	11,507	12,538	1,031	109.0%
運送費、保管料 Transportation and storage	478	446	△ 31	93.3%
広告宣伝費 Advertising	96	73	△ 23	75.9%
販売促進費 Sales promotion	732	646	△ 85	88.3%
研究開発費 Research and development	3,118	2,870	△ 248	92.0%
管理費、その他 Other, net	5,635	5,776	140	102.5%
販売費及び一般管理費 SG&A expenses	10,062	9,813	△ 248	97.5%
バイオ産業支援 Bioindustry	3,938	4,672	734	118.6%
遺伝子医療 Gene Therapy	△ 1,252	△ 730	521	−
医食品バイオ AgriBio	122	90	△ 32	73.6%
共通 Eliminations/Corporate	△ 1,363	△ 1,307	56	−
営業利益（△：損失） Operating income(Δ:loss)	1,444	2,724	1,280	188.6%
営業外収益 Non-operating income	258	186	△ 72	72.0%
営業外費用 Non-operating expenses	5	41	35	697.0%
経常利益（△：損失） Ordinary income(Δ:loss)	1,697	2,869	1,171	169.0%
特別利益 Extraordinary income	4	2	△ 1	63.5%
特別損失 Extraordinary loss	28	247	218	878.6%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	1,673	2,625	951	156.9%
法人税、住民税及び事業税 Current income taxes	1,168	1,222	53	104.6%
法人税等調整額 Deferred income taxes	△ 112	△ 150	△ 37	−
四半期純利益（△：損失） Net income(Δ:loss)	618	1,553	935	251.3%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	4	△ 7	△ 12	−
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	613	1,561	947	254.4%
設備投資額（有形・無形） Capital expenditures	1,850	1,200	△ 649	64.9%
減価償却費（有形・無形） Depreciation and Amortization	1,247	1,276	29	102.4%
のれん償却額 Amortization of goodwill	135	121	△ 13	89.8%

4. 平成29年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2016

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成28年3月期 第3四半期累計	平成29年3月期 第3四半期累計 Apr. 1, 2016 - Dec. 31, 2016	
	実績(a) FY2016(1Q-3Q) Actual (a)	実績(b) FY2017(1Q-3Q) Actual (b)	前期差 Change(b-a)
米ドル : US dollar	120.99	108.59	△ 12.40
ポンド: Pound	185.48	151.50	△ 33.98
ユーロ: Euro	134.75	121.10	△ 13.65
人民元: Yuan	19.33	16.48	△ 2.85
100ウォン: 100 Won	10.78	9.34	△ 1.44
インドルピー: Rupee	1.91	1.62	△ 0.29
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	14.38	12.93	△ 1.45
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	89.20	79.15	△ 10.05

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2016(1Q-3Q)
焼酎 Shochu	△ 17
清酒 Sake	△ 214
ソフトアルコール飲料 Light-alcohol refreshers	△ 3
その他酒類 Other liquors	△ 535
本みりん Hon Mirin	△ 47
その他調味料 Other seasonings	△ 34
原料用アルコール等 Raw alcohol	—
海外日本食材卸 Japanese food wholesale business in overseas markets	△ 2,186
その他 Other	—
宝酒造グループ 計 Net sales of Takara Shuzo Group	△ 3,039
研究用試薬 Research reagents	△ 1,381
理化学機器 Scientific instruments	△ 13
受託・その他 Contracted service and other	△ 99
バイオ産業支援 計 Bioindustry	△ 1,494
遺伝子医療 Gene Therapy	—
医食品バイオ AgriBio	—
タカラバイオグループ 計 Net sales of Takara Bio Group	△ 1,494
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 4,533

② 海外売上高比率の推移 :Change in overseas sales ratio

	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	平成29年3月期 第3四半期累計 FY2017(1Q-3Q)
宝酒造グループ Takara Shuzo Group	5.4%	7.9%	12.7%	14.9%	14.6%
タカラバイオグループ Takara Bio Group	41.8%	48.7%	53.1%	56.5%	53.6%
その他 Other	-	-	0.0%	-	-
宝ホールディングス Takara Holdings Inc. -Consolidated-	8.6%	11.9%	16.7%	19.7%	19.1%

③ 海外主要子会社の業績 :Financial Result of major overseas subsidiaries

		平成28年3月期第3四半期累計実績 FY2016(1Q-3Q) Actual		平成29年3月期 第3四半期累計実績 FY2017(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	22,082	2,779	23,461	2,873
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,671	336	2,547	312
宝酒造食品	千 元 :Thousands of Yuan	34,867	1,970	32,357	878
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	673	38	533	14
トマーチン	千 ポ ン ド :Thousands of Pound	11,684	2,441	10,042	1,958
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	2,167	452	1,521	296
エイジ・インターナショナル	千 US ドル :Thousands of US dollar	10,840	4,040	13,941	5,342
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	1,311	488	1,513	580
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	82,716	8,859	98,634	11,378
FOODEX Group	百 万 円 :Millions of Yen	11,145	1,193	11,944	1,377
タザキフーズ	千 ポ ン ド :Thousands of Pound	21,816	2,026	25,350	1,650
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	4,046	375	3,840	250
タカラバイオヨーロッパS.A.S.	千 ユ ー ロ :Thousands of Euro	12,368	1,482	14,039	1,699
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	1,666	199	1,700	205
タカラバイオヨーロッパAB	千 SEK :Thousands of Sweden Krona	22,760	Δ 10,865	20,976	Δ 10,644
Takara Bio Europe AB	百 万 円 :Millions of Yen	327	Δ 156	271	Δ 137
宝生物工程(大連)	千 元 :Thousands of Yuan	204,956	84,033	250,468	112,412
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	3,961	1,624	4,127	1,852
宝日医生物技術(北京)	千 元 :Thousands of Yuan	70,374	Δ 706	56,216	Δ 5,236
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	1,360	Δ 13	926	Δ 86
タカラコリアバイオメディカル	百 万 ウ ォ ン :Millions of Won	6,501	744	6,315	836
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	700	80	589	78
タカラバイオDSSインド	千インドルピー :Thousands of Rupee	136,644	4,908	136,075	Δ 10,293
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	260	9	220	Δ 16
タカラバイオUSA	千 US ドル :Thousands of US dollar	51,099	9,730	57,887	13,922
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	6,182	1,177	6,286	1,511

④ 宝酒造グループ 営業利益増減要因 :Factors of change in operating income of Takara Shuzo Group

(百万円 :Millions of Yen)

要因 Factors	対前期増減 Change from FY2016(1Q-3Q)	内容 Detail
売上総利益の増減 (宝酒造単体) Change in Gross profit of TAKARA SHUZO CO.,LTD.	+2,032	数量差 +1,381 単価差 +650 Change in quantities +1,381 Change in unit price +650 ➢主な内訳 Breakdown 焼酎△45(数量差△405 単価差+359) Shochu △45 (Change in quantities △405 Change in unit price +359) 清酒+46(数量差+136 単価差△90) Sake +46 (Change in quantities ;136 Change in unit price △90) ソフトアルコール飲料+1,289(数量差+1,140 単価差+149) Light-alcohol refreshers +1,289(Change in quantities +1,140 Change in unit price +149) 本みりん+158(数量差+60 単価差+97) Hon Mirin+158 (Change in quantities +60 Change in unit price +97) (参考)原価コストダウン +534 Reference :Cost reduction +534 ※上記数量差および単価差に含む *Included in changes above
販売費及び一般管理費の増減 (宝酒造単体) Change in SG&A expenses of TAKARA SHUZO CO.,LTD.	Δ 667	運送費の増加 △186 Change in Transportation and storage △186 広告宣伝費の減少 +85 Change in Advertising +85 販売促進費の増加 △554 Change in Sales promotion and allowance for s.p. △554
宝酒造単体 計 TAKARA SHUZO CO.,LTD.	+1,365	
その他の子会社における 営業利益の増減 Change in Operating income of other subsidiaries	Δ 37	海外日本食材卸会社 +101 ※のれん償却後 (フーデックスグループ +200、タザキフーズ △98 Japanese food wholesale business in overseas markets +101 FOODEX Group +200 TAZAKI FOODS LTD. △98 その他の海外子会社 △107 Other overseas subsidiaries △107 国内子会社 +96 Domestic subsidiaries +96 連結消去等 △128 Elimination of intra-company transactions,etc. △128
宝酒造グループ 計 Takara Shuzo Group	+1,328	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	平成29年3月期 第3四半期累計 FY2017(1Q-3Q)	前期対比 Change from FY2016(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	153,915	155,025	159,519	166,054	170,250	172,218	1,967	101.2%
売上原価	Cost of sales	93,282	94,618	98,027	100,975	102,349	101,336	△ 1,012	99.0%
（売上高原価率）	(Ratio to Net sales)	60.6%	61.0%	61.5%	60.8%	60.1%	58.8%	-1.3pt	–
売上総利益	Gross profit	60,633	60,407	61,491	65,078	67,901	70,881	2,980	104.4%
販売費及び一般管理費	SG&A expenses	50,907	51,246	52,599	54,497	57,809	58,139	330	100.6%
（売上高販管費率）	(Ratio to Net sales)	33.1%	33.1%	33.0%	32.8%	34.0%	33.8%	-0.2pt	–
営業利益（△：損失）	Operating income(Δ:loss)	9,725	9,160	8,891	10,580	10,091	12,741	2,649	126.3%
（売上高営業利益率）	(Ratio to Net Sales)	6.3%	5.9%	5.6%	6.4%	5.9%	7.4%	+1.5pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	23,723	24,283	24,214	23,957	24,561	25,020	459	101.9%
（売上高販促費率）	(Ratio to Net sales)	15.4%	15.7%	15.2%	14.4%	14.4%	14.5%	+0.1pt	–
研究開発費	R&D expenses	2,169	2,264	2,412	2,485	3,363	3,155	△ 208	93.8%
（売上高研究開発費率）	(Ratio to Net sales)	1.4%	1.5%	1.5%	1.5%	2.0%	1.8%	-0.1pt	–
設備投資額（有形・無形）	Capital expenditures	3,694	4,102	5,324	6,904	3,768	3,749	△ 19	99.5%
減価償却費（有形・無形）	Depreciation and Amortization	3,284	3,132	3,111	3,358	3,820	3,753	△ 67	98.2%
のれん償却額	Amortization of goodwill	206	201	265	350	404	349	△ 55	86.4%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	平成29年3月期 第3四半期累計 FY2017(1Q-3Q)	前期対比 Change from FY2016(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	137,671	138,367	140,850	146,178	146,859	148,818	1,959	101.3%
売上原価	Cost of sales	85,802	86,994	89,404	91,977	91,986	92,152	166	100.2%
（売上高原価率）	(Ratio to Net sales)	62.3%	62.9%	63.5%	62.9%	62.6%	61.9%	-0.7pt	–
売上総利益	Gross profit	51,868	51,372	51,446	54,200	54,872	56,666	1,793	103.3%
販売費及び一般管理費	SG&A expenses	43,813	43,789	44,404	45,764	46,787	47,252	465	101.0%
（売上高販管費率）	(Ratio to Net sales)	31.8%	31.6%	31.5%	31.3%	31.9%	31.8%	-0.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	8,055	7,582	7,041	8,435	8,085	9,413	1,328	116.4%
（売上高営業利益率）	(Ratio to Net sales)	5.9%	5.5%	5.0%	5.8%	5.5%	6.3%	+0.8pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	22,986	23,542	23,422	23,258	23,759	24,287	527	102.2%
（売上高販促費率）	(Ratio to Net sales)	16.7%	17.0%	16.6%	15.9%	16.2%	16.3%	+0.1pt	–
設備投資額（有形・無形）	Capital expenditures	1,647	1,735	1,969	3,463	1,783	1,675	△ 107	94.0%
減価償却費（有形・無形）	Depreciation and Amortization	2,369	2,205	2,143	2,294	2,396	2,298	△ 97	95.9%
のれん償却額	Amortization of goodwill	112	110	164	257	268	227	△ 41	84.6%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	平成29年3月期 第3四半期累計 FY2017(1Q-3Q)	前期対比 Change from FY2016(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	13,443	13,916	16,167	17,293	20,706	20,645	△ 61	99.7%
売上原価	Cost of sales	6,066	6,275	7,500	7,839	9,199	8,106	△ 1,093	88.1%
（売上高原価率）	(Ratio to Net sales)	45.1%	45.1%	46.4%	45.3%	44.4%	39.3%	-5.2pt	–
売上総利益	Gross profit	7,376	7,640	8,666	9,453	11,507	12,538	1,031	109.0%
販売費及び一般管理費	SG&A expenses	6,503	6,932	7,758	8,190	10,062	9,813	△ 248	97.5%
（売上高販管費率）	(Ratio to Net sales)	48.4%	49.8%	48.0%	47.4%	48.6%	47.5%	-1.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	872	707	908	1,263	1,444	2,724	1,280	188.6%
（売上高営業利益率）	(Ratio to Net sales)	6.5%	5.1%	5.6%	7.3%	7.0%	13.2%	+6.2pt	–
研究開発費	R&D expenses	1,896	1,993	2,154	2,225	3,118	2,870	△ 248	92.0%
（売上高研究開発費率）	(Ratio to Net sales)	14.1%	14.3%	13.3%	12.9%	15.1%	13.9%	-1.2pt	–
設備投資額（有形・無形）	Capital expenditures	589	2,058	3,230	3,380	1,850	1,200	△ 649	64.9%
減価償却費（有形・無形）	Depreciation and Amortization	811	817	849	956	1,247	1,276	29	102.4%
のれん償却額	Amortization of goodwill	93	90	100	92	135	121	△ 13	89.8%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	平成27年3月期 第3四半期累計 FY2015(1Q-3Q)	平成28年3月期 第3四半期累計 FY2016(1Q-3Q)	平成29年3月期 第3四半期累計 FY2017(1Q-3Q)	前期対比 Change from FY2016(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	1,910	1,612	1,027	1,230	1,376	1,337	△ 39	97.2%
売上原価	Cost of sales	1,240	1,013	475	597	650	510	△ 140	78.5%
（売上高原価率）	(Ratio to Net sales)	65.0%	62.9%	46.3%	48.6%	47.3%	38.2%	-9.1pt	–
売上総利益	Gross profit	669	598	551	632	725	826	100	113.9%
販売費及び一般管理費	SG&A expenses	756	621	546	602	685	813	128	118.7%
（売上高販管費率）	(Ratio to Net sales)	39.6%	38.6%	53.2%	49.0%	49.8%	60.8%	+11.1pt	–
営業利益（△：損失）	Operating income(Δ:loss)	△ 87	△ 22	5	30	40	13	△ 27	32.2%
（売上高営業利益率）	(Ratio to Net sales)	–	–	0.5%	2.4%	3.0%	1.0%	-2.0pt	–
ヘルスケア事業売上高	Net sales of Healthcare products	948	931	1,027	1,230	1,376	1,337	△ 39	97.2%
設備投資額（有形・無形）	Capital expenditures	31	1	2	2	5	7	1	133.1%
減価償却費（有形・無形）	Depreciation and Amortization	8	8	0	1	2	3	0	132.3%

6. 平成29年3月期 連結業績予想数値の修正 :Revision of Consolidated Business Results Forecast for the Year Ending March 31, 2017

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent	1株当り当期純利益 Net income per share
					円 銭 Yen
前回発表予想(平成28年11月10日発表)(A) Previous forecast (A) (Nov. 10, 2016, announcement)	234,100	12,600	13,300	8,200	40.75
今回修正予想(B) Revised forecast (B)	234,100	13,100	13,800	8,300	41.25
増減額(B−A) Difference (B−A)	0	500	500	100	―
増減率(%) Difference (%)	0.0	4.0	3.8	1.2	―
ご参考:前期実績(平成28年3月期) Reference: Previous business results (Year ended March 31, 2016)	225,364	11,680	12,840	7,055	35.06

宝酒造グループ :Takara Shuzo Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent
前回発表予想(平成28年11月10日発表)(A) Previous forecast (A) (Nov. 10, 2016, announcement)	201,600	9,200	9,400	6,700
今回修正予想(B) Revised forecast (B)	201,600	9,400	9,600	6,800
増減額(B−A) Difference (B−A)	0	200	200	100
増減率(%) Difference (%)	0.0	2.2	2.1	1.5
ご参考:前期実績(平成28年3月期) Reference: Previous business results (Year ended March 31, 2016)	192,025	8,410	8,726	5,474

タカラバイオグループ :Takara Bio Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent	1株当り当期純利益 Net income per share
					円 銭 Yen
前回発表予想(平成28年11月10日発表)(A) Previous forecast (A) (Nov. 10, 2016, announcement)	28,600	2,850	3,150	1,350	11.21
今回修正予想(B) Revised forecast (B)	29,100	3,100	3,430	1,350	11.21
増減額(B−A) Difference (B−A)	500	250	280	0	―
増減率(%) Difference (%)	1.7	8.8	8.9	0.0	―
ご参考:前期実績(平成28年3月期) Reference: Previous business results (Year ended March 31, 2016)	29,729	2,667	3,301	1,334	11.08